Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
The First Clinical College, Chongqing Medical University, Chongqing, China.
Front Immunol. 2023 Aug 15;14:1238647. doi: 10.3389/fimmu.2023.1238647. eCollection 2023.
Psoriasis is a chronic inflammatory skin disease with a prevalence of 0.14% to 1.99%. The underlying pathology is mainly driven by the abnormal immune responses including activation of Th1, Th17, Th22 cells and secretion of cytokines. Patients with psoriasis are more likely to develop cardiovascular disease (CVD) which has been well recognized as a comorbidity of psoriasis. As mediators of hemostasis and thromboinflammation, platelets play an important part in CVD. However, less is known about their pathophysiological contribution to psoriasis and psoriasis-associated CVD. A comprehensive understanding of the role of platelet activation in psoriasis might pave the path for more accurate prediction of cardiovascular (CV) risk and provide new strategies for psoriasis management, which alleviates the increased CV burden associated with psoriasis. Here we review the available evidence about the biomarkers and mechanisms of platelet activation in psoriasis and the role of platelet activation in intriguing the common comorbidity, CVD. We further discussed the implications and efficacy of antiplatelet therapies in the treatment of psoriasis and prevention of psoriasis-associated CVD.
银屑病是一种慢性炎症性皮肤病，患病率为 0.14%至 1.99%。其潜在的病理主要是由异常免疫反应驱动的，包括 Th1、Th17、Th22 细胞的激活和细胞因子的分泌。银屑病患者更容易发生心血管疾病（CVD），这已被公认为银屑病的一种合并症。作为止血和血栓炎症的介质，血小板在 CVD 中起着重要作用。然而，人们对它们在银屑病和银屑病相关 CVD 中的病理生理作用知之甚少。全面了解血小板激活在银屑病中的作用可能为更准确地预测心血管（CV）风险铺平道路，并为银屑病管理提供新的策略，从而减轻与银屑病相关的 CV 负担。在这里，我们回顾了关于血小板激活在银屑病中的生物标志物和机制以及血小板激活在诱发常见合并症、CVD 中的作用的现有证据。我们进一步讨论了抗血小板治疗在银屑病治疗和预防银屑病相关 CVD 中的意义和疗效。
